Lupus & antiphospholipid syndrome
Anifrolumab Versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus
Main finding · MIResult — go to the resultHazard ratio 0.63 95% CI 0.40–0.91Authors' conclusion
Anifrolumab treatment was associated with lower CVD risk compared with belimumab in patients with SLE
Study context
- Population
- Adults with systemic lupus erythematosus (SLE) initiating anifrolumab or belimumab without prior cardiovascular disease (CVD), TriNetX network, 2020–20251,084 matched pairs
- Participants
- 1,091 vs 7,492
- Exposure
- Anifrolumab vs belimumab
- Anifrolumabn = 1,091
- Belimumabn = 7,492reference
- Outcome
- Risks of myocardial infarction (MI), heart failure (HF), ischemic stroke and MACE
- Follow-up
- Three years
Methodological detailsretrospective cohort study, propensity-score matched, electronic health record data, 67 health care organizations, TriNetX network, Cox regression
- Retrospective cohort study
- Propensity-score matched
- Electronic health record data
- 67 health care organizations, TriNetX network
- Cox regression
Main finding
MI
Hazard ratio
0.63
95% CI 0.40–0.91
Anifrolumabvs Belimumab
HR 0.63 (95% CI 0.40–0.91)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| HF · three years | 0.55 (0.39–0.75) | |
| Ischemic stroke · three years | 0.50 (0.26–0.94) | |
| MACE · three years | 0.65 (0.37–0.89) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Anifrolumab Versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. Published 7 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →